Get started
Work

1300P Intracranial efficacy of brigatinib (BRG) vs crizotinib (CRZ): Updated results from the ALTA-1L trial

Year: 2020
Type: article
Study design: Clinical Trial
DOI: 10.1016/j.annonc.2020.08.1614
Authors: S. Popat, H.R. Kim, M-J. Ahn, J.C-H. Yang, J-Y. Han, M.J. Hochmair, K.H. Lee, A. Delmonte, M.R. Garcia Campelo, D-W. Kim, F. Griesinger, E. Felip, R. Califano, A. Spira, S. Gettinger, M. Tiseo, Q. Ni, P. Zhang, D.R. Camidge
Institutions: Royal Marsden Hospital, Yonsei University, Yonsei Cancer Hospital, Samsung Medical Center, National Taiwan University Hospital, National Cancer Center, Chungbuk National University, Chungbuk National University Hospital, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Complexo Hospitalario Universitario A Coruña, Seoul National University, Seoul National University Hospital, Carl von Ossietzky Universität Oldenburg, Pius Hospital Oldenburg, Vall d'Hebron Hospital Universitari, University of Manchester, The Christie NHS Foundation Trust, Virginia Cancer Specialists, Yale Cancer Center, University of Parma, Takeda Oncology (United States), University of Colorado Cancer Center
Language: English
Field: Medicine
Open Access status: bronze
Funders: Amgen, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, Sanofi, Astellas Pharma, Servier, Genentech, EMD Serono, Foundation Medicine
OpenAlex ID: W3088382755
FWCI: 0.423
Cites: 1
Cited by: 3
Related to: 10